I would say that stockholders are eagerly awaiting P2b top line results with a great degree of anticipation, not trepidation, in finding out just how efficacious Prurisol truly is as all pre-clinical work and the P2a indicates that the 300 dose arm should be about the prime sweet spot for Prurisol effectiveness. Just what that PASI number will be is still unknown, but I am sure all stockholders sure like our chances for great results.
On the other hand, those wanting the P2b trial to fail must be quaking in their boots because they know they don't have a leg to stand on in hoping for some safety issues and though they have tried to make a case that the P2a didn't statistically prove any Prurisol efficacy whatsoever, the chart showed a pretty straightforward solid rise in effectiveness compared to the 50 and 100 dosage arms.
Nice to finally be on the side that is now holding all the cards instead of IMO dancing to the tune of those that had no opposition to their misrepresentations of facts and stock price compression over the last year or two.
News 
Market Data 
Discover 
